A clinical study on local pharmacokinetics and safety of DTBF in patients with superficial bladder cancer
Latest Information Update: 13 Oct 2016
Price :
$35 *
At a glance
- Drugs Deuteporfin (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Pharmacokinetics
- 07 Oct 2016 Status changed from recruiting to completed.
- 29 Apr 2016 Planned number of patients changed from 26 to 20.
- 29 Apr 2016 Status changed from not yet recruiting to recruiting.